Skip to main content

BioHarvest Sciences Chief Medical Officer to Speak at Collision Conference in Toronto

By: Newsfile

Dr. Brian Cornblatt will give the keynote address on the "HealthConf" Stage at Collision

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 27, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") has been invited to one of the largest and fastest-growing technology conferences in North America. Its Chief Medical Officer, Dr. Brian Cornblatt, will deliver the keynote speech on the "HealthConf" stage at Collision on Thursday, June 29th at 10:45 am EST.

After his keynote address, Dr. Cornblatt will host the stage throughout the afternoon. Dr. Cornblatt will also lead a roundtable discussion titled, ""Can biotech and tech help build products sustainably?" on Wednesday, June 28, at 11:00 AM EST - around how technology can help enhance sustainability in production, especially in regards to plants and medicines.

"I am looking forward to the opportunity to bring BioHarvest to such a large international stage with an audience of people looking to make a difference in technology," says Dr. Cornblatt. "For the first time, I will be publicly sharing the personal journey that brought me to believe in nutraceuticals and ultimately in BioHarvest's botanical synthesis technology, which I believe is about to disrupt the nutraceutical industry."

About Collision
The Collision Conference is a rapidly growing technology conference in North America organized by its parent Web Summit. The 2023 Collision Conference runs from June 26-29th in Toronto.

About BioHarvest Sciences
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals - nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (API's) that focus on specific medical indications.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For investor or media information, please contact:
Investor Relations
Phone: 778.686.3855

For VINIA information, please contact:
VINIA Customer Success Team
Phone: 1.888.882.2023

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

All forward-looking statements are inherently uncertain and actual results may be affected by material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.